Myocardial ischemia is a cardiovascular disorder that causes angina, shortness of breath and cardiac arrhythmias. Myocardial ischemia is one of the reasons of the sudden cardiac death. Due to obstruction of coronary blood flow, oxygen and glucose flow is interrupted that causes impairment of cellular metabolism. In an electrocardiogram, the ST-segment depression is observed as the clinical sign of myocardial ischemia. Myocardial ischemia can be diagnosed by echocardiogram, electrocardiogram, cardiac computed tomography, stress test, coronary angiography, and nuclear scan test. Certain procedures also follow in case of myocardial ischemia such as coronary artery bypass surgery, enhanced external counterpulsation, and angioplasty and stenting. First Affiliated Hospital of Harbin Medical University is in the process of developing ticagrelor as a platelet ADP receptor antagonist for the treatment of myocardial ischemia. University Health Network, Toronto is in the process of developing atorvastatin as a HMG-CoA reductase inhibitor for the treatment of myocardial ischemia. Some of the companies having the pipeline of myocardial ischemia include Janssen Research & Development, LLC, AstraZeneca plc, Gilead Sciences, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.